Canonical ingredient

DL-Leucine

LEUCINE

37 linked products

Official identifiers

CAS 328-39-2 ChEBI CHEBI:25017 InChI InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)InChIKey ROHFNLRQFUQHCH-UHFFFAOYSA-N KEGG_COMPOUND C16439 SMILES CC(C)CC(N)C(=O)O

Names and synonyms

DL-Leucine (en)
leucine (en)
Leucine (fr)
D2-Leucine (fr-CA)

Source-scoped chemical properties

Every value keeps its own authority, licence and retrieval date. Conflicting values are not silently merged.

canada dsl listing: listed; canada_dsl_categorization · Open Government Licence - Canada 2.0 · 2026-08-03
dsl bioaccumulative: No; canada_dsl_categorization · Open Government Licence - Canada 2.0 · 2026-08-03
dsl inherently toxic aquatic: No; canada_dsl_categorization · Open Government Licence - Canada 2.0 · 2026-08-03
dsl meets cepa categorization: No; canada_dsl_categorization · Open Government Licence - Canada 2.0 · 2026-08-03
dsl meets environmental: No; canada_dsl_categorization · Open Government Licence - Canada 2.0 · 2026-08-03
dsl meets human health: No; canada_dsl_categorization · Open Government Licence - Canada 2.0 · 2026-08-03
dsl persistent: No; canada_dsl_categorization · Open Government Licence - Canada 2.0 · 2026-08-03
dsl substance category: Organics; canada_dsl_categorization · Open Government Licence - Canada 2.0 · 2026-08-03

Safety and technical documents

General references and manufacturer-specific SDS documents are kept separate.

0 document(s)

No verified SDS or technical sheet is linked yet. This absence is explicit and does not mean that no document exists.

End-to-end traceability

Only links supported by an identified source are published. Missing evidence remains explicitly unknown.

Partial chain

Evidence still missing

Country or region of origin
Raw-material producer
Ingredient manufacturer
Distributor
Transformation steps

Documented origins

No origin has been proven yet by an explicit source.

Documented organizations

No organization has been proven yet by an explicit source.

Documented transformations

No transformation step has been proven yet by an explicit source.

Method: a company’s registration country is never used as evidence of a material’s origin.

Products containing this ingredient

1.08 · G · 100 · ML

8.5% FREAMINE III

770 · MG · 100 · ML

AMINO ACID FORMULA INJ

28.5 · MG · L

AMINO ACID FORMULA INJ

28.5 · MG · L

4 · MG · 100 · ML

AMINO ACID INJECTABLE

5.4 · MG · 100 · ML

AMINO BOLUSES IMPROVED

4 · MG · 100 · ML

4 · MG · 100 · ML

AMINO SOLUTION INJ

4 · MG · 100 · ML

AMINO SOLUTION INJ

4 · MG · 100 · ML

2.5 · MG · 100 · ML

AMINOLEAN INJECTION

2.5 · MG · 100 · ML

AMINOSYN 10% W ELECTROLYTES

940 · MG · 100 · ML

AMINOSYN 3.5% M

329 · MG · 100 · ML

AMINOSYN 8.5% INJECTION WITH ELECTROLYTES

810 · MG · 100 · ML

AMINOSYN II 5% INJ

500 · MG · 100 · ML

AMINOSYN RF INJECTION

726 · MG · 100 · ML

1.38 · G · 100 · ML

BVS AMINO ACID SOLUTION INJ

4 · MG · 100 · ML

0.74 · G · 100 · ML

Enhanced Collagen

Marine Collagen

NEPHRAMINE LIQ IV

880 · MG · 100 · ML

102 · MG · 100 · ML

0.38 · G · 100 · ML

SMOFKABIVEN ELECTROLYTE FREE

0.38 · G · 100 · ML

SMOFKABIVEN EXTRA NITROGEN

0.48 · G · 100 · ML

SMOFKABIVEN EXTRA NITROGEN ELECTROLYTE FREE

0.48 · G · 100 · ML

SMOFKABIVEN PERIPHERAL

230 · MG · 100 · ML

620 · MG · 100 · ML

730 · MG · 100 · ML

TRAVASOL AMINO ACID INJ 5.5%

340 · MG · 100 · ML

TRAVASOL AMINO ACID INJ 8.5%

526 · MG · 100 · ML

620 · MG · 100 · ML

TRAVASOL INJ WITHOUT ELECTROLYTES 5.5%

340 · MG · 100 · ML

TRAVASOL INJ WITHOUT ELECTROLYTES 8.5%

526 · MG · 100 · ML